brl 42810 has been researched along with B Virus Infection in 44 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herpes virus type 1 and rarely type 2 may lead to painful and resistant oral ulcers, and systemic treatment with acyclovir, valaciclovir or famciclovir is indicated." | 4.79 | Viral lesions of the mouth in HIV-infected patients. ( Itin, PH; Lautenschlager, S, 1997) |
| "64 h; elimination half-life was 2." | 2.77 | Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study. ( Covert, JC; Maggs, DJ; Stanley, SD; Thomasy, SM, 2012) |
| " Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy." | 2.40 | New therapeutic approaches to the alphaherpesvirus infections. ( Cassady, KA; Whitley, RJ, 1997) |
| "Famciclovir, a synthetic acyclic guanine derivative, is a prodrug which, after oral administration, is rapidly metabolised to the highly bioavailable antiviral compound penciclovir." | 2.39 | Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. ( Perry, CM; Wagstaff, AJ, 1995) |
| " Dosage adjustment is required in the presence of renal impairment." | 2.39 | Pharmacokinetics of new antiherpetic agents. ( Rolan, P, 1995) |
| "Foscarnet treatment has been used with some clinical benefit in patients with acyclovir-resistant HSV or VZV, or ganciclovir-resistant CMV." | 2.39 | Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. ( Reusser, P, 1996) |
| " When administered orally, faMciclovir, the oral prodrug of PCV, is better absorbed than acyclovir, yielding an absolute bioavailability of PCV of 77%." | 2.39 | Famciclovir for treatment of herpesvirus infections. ( Flaherty, JF; Luber, AD, 1996) |
| " Further studies are needed to assess whether a famciclovir dosage of 90 versus 40 mg/kg, PO, 3 times/d would result in increased efficacy and shorter treatment time." | 1.43 | Oral administration of famciclovir for treatment of spontaneous ocular, respiratory, or dermatologic disease attributed to feline herpesvirus type 1: 59 cases (2006-2013). ( Freeman, KS; Kass, PH; Lim, CC; Maggs, DJ; Outerbridge, CA; Shull, O; Strom, AR; Thomasy, SM, 2016) |
| " The concentrations of penciclovir declined in a biphasic manner after the peak concentration was attained." | 1.36 | Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. ( Kondo, T; Kurosawa, M; Matsumura, T; Nagata, S; Nemoto, M; Tsujimura, K; Yamada, M; Yamanaka, T, 2010) |
| " More rigorous clinical trials are required to optimise the dosing regimen for safe and effective specific anti-herpes treatment in feline clinical medicine." | 1.35 | Treatment of feline herpesvirus-1 associated disease in cats with famciclovir and related drugs. ( Graham, PG; Lessels, NS; Malik, R; Meek, M; Norris, JM; Power, H; Vitale, C; Webb, S, 2009) |
| "The short course of the herpesvirus infections, with sudden deaths in all but the two surviving elephants, was ascribed to acute cardiac failure attributed to herpesvirus-induced capillary injury with extensive myocardial hemorrhage and edema." | 1.31 | Clinical and pathological findings of a newly recognized disease of elephants caused by endotheliotropic herpesviruses. ( Bengis, RG; Cambre, RC; Hamzeh, FM; Hardy, D; Hayward, GS; Hildbrandt, T; Montali, RJ; Richman, LK; Schmitt, D; Shahkolahi, A, 2000) |
| " The pharmacokinetics of famciclovir allow a more convenient dosing schedule than the schedule used with acyclovir." | 1.30 | Famciclovir: a new systemic antiviral agent for herpesvirus infections. ( Stott, GA, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (29.55) | 18.2507 |
| 2000's | 12 (27.27) | 29.6817 |
| 2010's | 17 (38.64) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Iyer, ML | 1 |
| Molter, CM | 1 |
| Flanagan, JP | 3 |
| Bauer, KL | 1 |
| Bernardy, R | 1 |
| Hoffman, D | 1 |
| Parkinson, L | 1 |
| Brainard, BM | 1 |
| Evans, TS | 1 |
| Pursell, T | 1 |
| Ling, PD | 4 |
| Mironovich, MA | 1 |
| Yoon, A | 1 |
| Marino, ME | 1 |
| Ineck, NE | 1 |
| Liu, CC | 1 |
| Carter, RT | 1 |
| Lewin, AC | 1 |
| Bronson, E | 1 |
| McClure, M | 1 |
| Sohl, J | 1 |
| Wiedner, E | 1 |
| Cox, S | 1 |
| Latimer, EM | 1 |
| Pearson, VR | 1 |
| Hayward, GS | 3 |
| Fuery, A | 3 |
| Cooper, AE | 1 |
| Thomasy, SM | 5 |
| Drazenovich, TL | 1 |
| Kass, PH | 3 |
| Potnis, SS | 1 |
| Leutenegger, CM | 2 |
| Maggs, DJ | 5 |
| Wissink-Argilaga, N | 1 |
| Dastjerdi, A | 2 |
| Molenaar, FM | 1 |
| Field, HJ | 2 |
| Vere Hodge, RA | 1 |
| Litster, AL | 1 |
| Lohr, BR | 1 |
| Bukowy, RA | 1 |
| Lamm, CG | 1 |
| Dean, SL | 1 |
| Estrada, MM | 1 |
| Smith, SG | 1 |
| Flacke, GL | 1 |
| Schmidt-Küntzel, A | 1 |
| Marker, L | 1 |
| Browning, GR | 1 |
| Tan, J | 2 |
| Long, S | 1 |
| Cox, SK | 1 |
| Tocidlowski, ME | 2 |
| Howard, LL | 2 |
| Peng, R | 1 |
| Shull, O | 1 |
| Outerbridge, CA | 1 |
| Lim, CC | 2 |
| Freeman, KS | 1 |
| Strom, AR | 1 |
| Seilern-Moy, K | 1 |
| Darpel, K | 1 |
| Steinbach, F | 1 |
| Molenaar, F | 1 |
| Malik, R | 1 |
| Lessels, NS | 1 |
| Webb, S | 1 |
| Meek, M | 1 |
| Graham, PG | 1 |
| Vitale, C | 1 |
| Norris, JM | 1 |
| Power, H | 1 |
| Tsujimura, K | 1 |
| Yamada, M | 1 |
| Nagata, S | 1 |
| Yamanaka, T | 1 |
| Nemoto, M | 1 |
| Kondo, T | 1 |
| Kurosawa, M | 1 |
| Matsumura, T | 1 |
| Mubareka, S | 1 |
| Leung, V | 1 |
| Aoki, FY | 1 |
| Vinh, DC | 1 |
| Reilly, CM | 1 |
| Lappin, MR | 1 |
| Cattamanchi, A | 1 |
| Saracino, M | 1 |
| Selke, S | 1 |
| Huang, ML | 1 |
| Magaret, A | 1 |
| Celum, C | 1 |
| Corey, L | 1 |
| Wald, A | 1 |
| Casper, C | 1 |
| Nolen, RS | 1 |
| Covert, JC | 1 |
| Stanley, SD | 1 |
| Roustan, G | 1 |
| Portero, F | 1 |
| Martín, P | 1 |
| Angel, A | 1 |
| Jeffries, P | 1 |
| Valente, P | 1 |
| Hospodar, E | 1 |
| Fowler, L | 1 |
| Tan, HH | 1 |
| Goh, CL | 1 |
| Perry, CM | 1 |
| Wagstaff, AJ | 1 |
| Rolan, P | 1 |
| Vesikari, T | 2 |
| Whitley, RJ | 2 |
| Thackray, AM | 1 |
| Reusser, P | 1 |
| Luber, AD | 1 |
| Flaherty, JF | 1 |
| Itin, PH | 1 |
| Lautenschlager, S | 1 |
| Cassady, KA | 1 |
| Stott, GA | 1 |
| Grose, C | 1 |
| Wiedeman, J | 1 |
| Wooley, P | 1 |
| Richman, LK | 3 |
| Montali, RJ | 2 |
| Cambre, RC | 1 |
| Schmitt, D | 1 |
| Hardy, D | 1 |
| Hildbrandt, T | 1 |
| Bengis, RG | 1 |
| Hamzeh, FM | 1 |
| Shahkolahi, A | 1 |
| Bowers, M | 1 |
| Fickel, J | 1 |
| Montali, R | 1 |
| Schaftenaar, W | 1 |
| Göritz, F | 1 |
| Hildebrandt, TB | 1 |
| Pitra, C | 1 |
| Schmitt, DL | 1 |
| Hardy, DA | 1 |
| Lindsay, WA | 1 |
| Isaza, R | 1 |
| West, G | 1 |
| Dekker, CL | 1 |
| Prober, CG | 1 |
| Paavonen, J | 1 |
| Naesens, L | 1 |
| De Clercq, E | 1 |
| Gilmour, TK | 1 |
| Meyer, PA | 1 |
| Rytina, E | 1 |
| Todd, PM | 1 |
15 reviews available for brl 42810 and B Virus Infection
| Article | Year |
|---|---|
Recent developments in anti-herpesvirus drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Herpesviridae Infections; Herpesvirus Vacci | 2013 |
Famciclovir: a focus on efficacy and safety.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Female; Hepatitis B; Hepatitis B virus; Herpesviridae | 2010 |
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Ad | 2006 |
Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections.
Topics: 2-Aminopurine; Absorption; Administration, Oral; Aging; Antiviral Agents; Controlled Clinical Trials | 1995 |
Pharmacokinetics of new antiherpetic agents.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Famciclovir; Guanine; Herpesviridae Infections; | 1995 |
[New medication for herpesvirus infections].
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Herpesviridae Infections; Humans; Prodrugs; | 1995 |
Advances in the management of herpesvirus infections. Introduction.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Guanine; Herpes Zoster; Herpesviridae Infec | 1996 |
Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Microbial; Famcicl | 1996 |
Famciclovir for treatment of herpesvirus infections.
Topics: 2-Aminopurine; Antiviral Agents; Drug Interactions; Famciclovir; Herpesviridae Infections; Humans; P | 1996 |
Viral lesions of the mouth in HIV-infected patients.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cytomegalovirus In | 1997 |
New therapeutic approaches to the alphaherpesvirus infections.
Topics: 2-Aminopurine; Acyclovir; Alphaherpesvirinae; Antibodies, Monoclonal; Arabinofuranosyluracil; Cidofo | 1997 |
Generic acyclovir vs. famciclovir and valacyclovir.
Topics: 2-Aminopurine; Acyclovir; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Clinical Tri | 1997 |
Pediatric uses of valacyclovir, penciclovir and famciclovir.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Child; Drug Approval; Famciclovir; Guanine; Herpesvirida | 2001 |
[Antiviral agents and the practicing physician].
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Family Practice; Female; Herpesviridae Infe | 2000 |
Recent developments in herpesvirus therapy.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Arabinofuranosyluracil; Bromodeoxyuridine; Cidofovir; Cl | 2001 |
6 trials available for brl 42810 and B Virus Infection
| Article | Year |
|---|---|
Evaluation of compounded cidofovir, famciclovir, and ganciclovir for the treatment of feline herpesvirus ocular surface disease in shelter-housed cats.
Topics: Animals; Antiviral Agents; Cat Diseases; Cats; Cidofovir; Famciclovir; Ganciclovir; Herpesviridae In | 2023 |
Prophylactic and therapeutic effects of twice-daily famciclovir administration on infectious upper respiratory disease in shelter-housed cats.
Topics: Animals; Antibiotic Prophylaxis; Antiviral Agents; Cat Diseases; Cats; Famciclovir; Female; Herpesvi | 2019 |
Clinical and antiviral effect of a single oral dose of famciclovir administered to cats at intake to a shelter.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Cat Diseases; Cats; Dose-Response Relationship, Drug; Famc | 2015 |
Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1.
Topics: 2-Aminopurine; Administration, Oral; Animals; Antiviral Agents; Cat Diseases; Cats; Famciclovir; Her | 2011 |
Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.
Topics: 2-Aminopurine; Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, High | 2011 |
Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Animals; Antiviral Agents; Cats; Dose-Response Relat | 2012 |
23 other studies available for brl 42810 and B Virus Infection
| Article | Year |
|---|---|
NOVEL DIAGNOSTIC AND THERAPEUTIC APPROACHES TO ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 1A HEMORRHAGIC DISEASE IN A CAPTIVE JUVENILE ASIAN ELEPHANT (
Topics: Animals; Elephants; Famciclovir; Herpesviridae; Herpesviridae Infections; Viremia | 2022 |
EPIDEMIOLOGIC EVALUATION OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 3B INFECTION IN AN AFRICAN ELEPHANT (LOXODONTA AFRICANA).
Topics: 2-Aminopurine; Animals; Antiviral Agents; Elephants; Famciclovir; Herpesviridae; Herpesviridae Infec | 2017 |
USING IN-HOUSE HEMATOLOGY TO DIRECT DECISION-MAKING IN THE SUCCESSFUL TREATMENT AND MONITORING OF A CLINICAL AND SUBSEQUENTLY SUBCLINICAL CASE OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 1B.
Topics: Animals; Animals, Zoo; Antiviral Agents; Cell Differentiation; DNA, Viral; Elephants; Famciclovir; H | 2019 |
Pathology in Practice. Herpesviral dermatitis.
Topics: 2-Aminopurine; Animals; Animals, Wild; Antiviral Agents; Cat Diseases; Cats; Dermatitis; Diagnosis, | 2015 |
TREATMENT OF CHRONIC HERPESVIRAL DERMATITIS IN A CAPTIVE CHEETAH (ACINONYX JUBATUS) IN NAMIBIA.
Topics: 2-Aminopurine; Acinonyx; Animals; Antiviral Agents; Chronic Disease; Cryotherapy; Famciclovir; Herpe | 2015 |
CLINICAL INFECTION OF CAPTIVE ASIAN ELEPHANTS (ELEPHAS MAXIMUS) WITH ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 4.
Topics: 2-Aminopurine; Animals; Animals, Zoo; Antiviral Agents; Base Sequence; DNA, Viral; Elephants; Famcic | 2016 |
CLINICAL INFECTION OF TWO CAPTIVE ASIAN ELEPHANTS (ELEPHAS MAXIMUS) WITH ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 1B.
Topics: 2-Aminopurine; Animals; Animals, Zoo; Antiviral Agents; Elephants; Famciclovir; Herpesviridae; Herpe | 2016 |
Oral administration of famciclovir for treatment of spontaneous ocular, respiratory, or dermatologic disease attributed to feline herpesvirus type 1: 59 cases (2006-2013).
Topics: 2-Aminopurine; Administration, Oral; Animals; Antiviral Agents; Cat Diseases; Cats; Conjunctivitis, | 2016 |
Surviving and fatal Elephant Endotheliotropic Herpesvirus-1A infections in juvenile Asian elephants - lessons learned and recommendations on anti-herpesviral therapy.
Topics: 2-Aminopurine; Animals; Animals, Zoo; Antiviral Agents; DNA, Viral; Elephants; Famciclovir; Fatal Ou | 2016 |
Treatment of feline herpesvirus-1 associated disease in cats with famciclovir and related drugs.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Australia; Cat Diseases; Cats; Conjunctivitis, Viral; Corn | 2009 |
Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Animals; Antiviral Agents; Area Under Curve; Famcicl | 2010 |
Herpesvirus claims another elephant as search for answers continues.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Elephants; Famciclovir; Genome, Viral; Herpesviridae; Herp | 2011 |
[Acute vesicular eruption over the trunk].
Topics: 2-Aminopurine; Adult; Anti-Bacterial Agents; Cefadroxil; Darier Disease; Famciclovir; Giant Cells; H | 2002 |
Herpes virus infection in peritoneal fluid: a case report and review of literature.
Topics: 2-Aminopurine; Aged; Antiviral Agents; Ascites; Ascitic Fluid; Cytodiagnosis; Famciclovir; Female; H | 2005 |
Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model.
Topics: 2-Aminopurine; 3T3 Cells; Acyclovir; Animals; Antiviral Agents; Brain Stem; Ear, External; Famciclov | 1996 |
Famciclovir: a new systemic antiviral agent for herpesvirus infections.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Herpesviridae Infections; Humans; Prodrugs | 1997 |
Famciclovir to treat herpesviruses.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Herpesviridae Infections; Humans; Prodrugs | 1998 |
Clinical and pathological findings of a newly recognized disease of elephants caused by endotheliotropic herpesviruses.
Topics: 2-Aminopurine; Acyclovir; Animals; Animals, Zoo; Antiviral Agents; DNA, Viral; Elephants; Endotheliu | 2000 |
Herpesviruses.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Arabinofuranosyluracil; Cidofovir; Complementary Therapi | 1995 |
A variant of the endotheliotropic herpesvirus in Asian elephants (Elephas maximus) in European zoos.
Topics: 2-Aminopurine; Amino Acid Sequence; Animals; Animals, Zoo; Antiviral Agents; Base Sequence; DNA, Vir | 2001 |
Use of famciclovir for the treatment of endotheliotrophic herpesvirus infections in Asian elephants (Elephas maximus).
Topics: 2-Aminopurine; Animal Diseases; Animals; Antiviral Agents; Edema; Elephants; Famciclovir; Female; He | 2000 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Administration, Topical; Amantadine; Animals; Antivi | 2002 |
Antiepiligrin (laminin 5) cicatricial pemphigoid complicated and exacerbated by herpes simplex virus type 2 infection.
Topics: 2-Aminopurine; Anti-Inflammatory Agents; Antiviral Agents; Cell Adhesion Molecules; Drug Therapy, Co | 2001 |